{"id":"NCT00696800","sponsor":"Organon and Co","briefTitle":"A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787)","officialTitle":"A Phase III, Randomized, Double-Blind, Active-Controlled, Non-Inferiority Clinical Trial to Investigate the Efficacy and Safety of a Single Injection of Org 36286 (Corifollitropin Alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation Using Daily Recombinant FSH as Reference","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06-27","primaryCompletion":"2007-11-19","completion":"2008-01-15","firstPosted":"2008-06-13","resultsPosted":"2014-08-21","lastUpdate":"2024-06-20"},"enrollment":1509,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["In Vitro Fertilization"],"interventions":[{"type":"DRUG","name":"Corifollitropin alfa","otherNames":["MK-8962","SCH 900962","Org 36286"]},{"type":"BIOLOGICAL","name":"RecFSH / Follitropin beta (Days 1 to 7)","otherNames":["Puregon / Follistim AQ Cartridge"]},{"type":"DRUG","name":"Placebo Corifollitropin alfa","otherNames":[]},{"type":"DRUG","name":"Placebo RecFSH / follitropin beta","otherNames":[]},{"type":"BIOLOGICAL","name":"RecFSH / Follitropin beta (Days 8 to hCG)","otherNames":["Puregon / Follistim AQ Cartridge"]},{"type":"DRUG","name":"Ganirelix","otherNames":["Orgalutran/ Ganirelix Acetate Injection"]},{"type":"BIOLOGICAL","name":"hCG","otherNames":["Pregnyl / urinary hCG"]},{"type":"BIOLOGICAL","name":"Progesterone","otherNames":[]}],"arms":[{"label":"150 µg Corifollitropin Alfa","type":"EXPERIMENTAL"},{"label":"200 IU recFSH","type":"ACTIVE_COMPARATOR"}],"summary":"To investigate the efficacy and safety of a single injection of 150 μg Corifollitropin Alfa (Organon 36286) to induce multifollicular development for controlled ovarian stimulation using daily recombinant FSH (recFSH) as a reference. The primary hypothesis is that a single injection of Corifollitropin Alfa is non-inferior to daily treatment with recFSH in initiating multifollicular growth.","primaryOutcome":{"measure":"Percentage of Participants With an Ongoing Pregnancy (Ongoing Pregnancy Rate)","timeFrame":"Assessed at least 10 weeks after embryo transfer (up to 1 year)","effectByArm":[{"arm":"150 µg Corifollitropin Alfa","deltaMin":39,"sd":null},{"arm":"200 IU recFSH","deltaMin":38.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":21},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27619773","26991902","26950065","24903202","23758821","20843746","19684043"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":755},"commonTop":["Procedural pain","Headache","Pelvic pain","Pelvic discomfort","Nausea"]}}